Following on from information provided to NICE by the company in February 2022, the appraisal of Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3781 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 February 2023 | Discontinued. Following on from information provided to NICE by the company in February 2022, the appraisal of Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 01 February 2022 | Suspended. For information, the company have announced that TRYbeCA-1 Phase 3 Trial did not meet its primary endpoint in Eryaspase in patients with second-line advanced pancreatic cancer and therefore they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes |
| 01 April 2020 | Topic has been referred |
For further information on our processes and methods, please see our CHTE processes and methods manual